ClinicalTrials.gg
RecruitingNCT05328024IPRICEUpdated Jun 5, 2026

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

An observational study in Head and Neck Cancer, sponsored by Centre Paul Strauss. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Centre Paul Strauss · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Head and Neck Neoplasms with a site in France — 49 open to participants now, 69 under way, 11 of them phase 3. Head and Neck Neoplasms · France.

Planned enrollment
28th of 38
60 · median 121
Started
2023
with 12 others
Observational
38 of 236
10 open now
Primary completion
2029-08
later than 56 of 68 live
Registered
186th of 236
by date

Among the 236 studies in Head and Neck Neoplasms with a site in France, this one is the 28th largest by planned enrollment of the 38 observational ones that give a count, is one of 13 that started in 2023, is one of 38 observational ones, reaches primary completion later than 56 of the 68 other live ones, and was the 186th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

49 of the 236 studies in Head and Neck Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Head and Neck Neoplasms with a site in France, or all of them as a file.
02

Study summary

This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.

Read the detailed description

Tumor and blood samples will be collected on patients treated by anti-PD1 immunotherapy at different timepoints. Tumor samples will be collected (i) before initiation of immunotherapy, (ii) at 50 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at 50 days after initiation of chemotherapy. Blood samples will be collected : (i) before initiation of immunotherapy, (ii) at each cycles of treatment until 84 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at each cycle until 50 days after initiation of chemotherapy (maximum 2 samples per month).

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease and with an indication to treatment by anti-PD1 immunotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with disease
  • Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise under local anesthesia
  • Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
  • Performance status 0, 1 or 2
  • At least one on V1.1 criteria

Exclusion criteria

Exclusion Criteria:

  • Head and neck squamous cell carcinoma accessible to a local treatment
  • Cancer of nasopharynx, sinus or nasal cavity
  • Other histology than epidermoid
  • Patients with for anti-PD1 immunotherapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Recurrent and/or metastatic head and neck carcinoma

    Patients with indication of anti-PD1 immunotherapy according to recommendations

    Drug: Immunotherapy

Interventions

  • DrugImmunotherapy

    anti-PD1

06

What researchers measure

Primary outcomes

  1. prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.

    objective response according to RECIST v1.1 (response evaluation criteria in solid tumours)

    Time frame: at 3 months after initiation of immunotherapy

  2. prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.

    objective response according to iRECIST criteria (immune response evaluation criteria in solid tumours)

    Time frame: at 3 months after initiation of immunotherapy

Secondary outcomes

  1. Prospective validation of the expression of interferon-gamma signature to predict progression free survival.

    Time from date of inclusion to the event of tumor recurrence or clinical progression or radiological progression on primary tumor or on lymph nodes or on metastasis or death whatever the cause.

    Time frame: at 3 years after inclusion

  2. Prospective validation of the expression of interferon-gamma signature to predict overall survival.

    Time from date of inclusion to death whatever the cause.

    Time frame: at 3 years after inclusion

  3. Prospective validation of the expression of interferon-gamma signature to predict duration of objective response.

    Time from date of first observation of objective response to progressive disease according to RECIST v1.1 or death..

    Time frame: at 3 years after inclusion

  4. Exploratory outcome : investigation of the expression of other molecular signatures such as immune cells panel within the tumor microenvironment to predict anti-PD1 immunotherapy response.

    objective response according to RECIST v1.1

    Time frame: at 3 months after initiation of immunotherapy

  5. Exploratory outcome : investigation of the expression of other molecular signatures such as immune checkpoints protein expression level to predict anti-PD1 immunotherapy response.

    objective response according to RECIST v1.1

    Time frame: at 3 months after initiation of immunotherapy

  6. Exploratory outcome : investigation of the expression of other molecular signatures such as biomarkers expression level involved in immunogenic cell death and in mitophagy to predict anti-PD1 immunotherapy response.

    objective response according to RECIST v1.1

    Time frame: at 3 months after initiation of immunotherapy

  7. Exploratory outcome : investigation of the expression of other molecular signatures such as protein expression level involved in hypoxia to predict anti-PD1 immunotherapy response.

    objective response according to RECIST v1.1

    Time frame: at 3 months after initiation of immunotherapy

07

Study locations

1 of 1 sites recruiting
  • Institut de cancérologie Strasbourg Europe
    Strasbourg, France 67033, France
    Recruiting
    • Mickaël BURGY · Contact
    • Mickaël BURGY · Principal investigator
08

References and documents

Publications

  • Helene C, Conrad O, Pflumio C, Borel C, Voegelin M, Bernard A, Schultz P, Onea MA, Jung A, Martin S, Burgy M. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study. BMC Cancer. 2023 Dec 8;23(1):1209. doi: 10.1186/s12885-023-11672-x. PubMed 38066522 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2029, 72 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 72 months is close to that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Aug 25, 2023
Primary completionEst.
Aug 25, 2029
CompletionEst.
Aug 25, 2029
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05328024
Lead sponsor
Centre Paul Strauss
Collaborators
Centre National de la Recherche Scientifique, France, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Aug 25, 2023
Primary completion
Aug 25, 2029 (estimated)
Completion
Aug 25, 2029 (estimated)
Last update
Jun 5, 2026

Study contacts

Valérie SARTORI
Contact
promotion-rc@icans.eu
03 68 33 95 23
Manon VOEGELIN
Contact
promotion-rc@icans.eu
03 68 33 95 23

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion